Segment Information

9 Months Ended

Sep. 30, 2022

Segment Information

Segment Information

14. Segment Information

The Company has two reportable segments-human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is approved by the U.S. FDA for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The accounting policies of the segments are the same as those described in the summary of significant accounting policies.

The Company's reportable segments net revenues and net loss for the three and nine months ended September 30, 2022, and 2021 consisted of the following:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in thousands)	2022		2021		2022		2021
	(unaudited)				(unaudited)
Revenue from external customers
Human Health	$	3,133	$	615	$	8,513	$	2,200
Animal Health		17		15		183		55
Consolidated Totals	$	3,150	$	630	$	8,696	$	2,255
Segment net income (loss)
Human Health	$	(6,360)	$	(5,698)	$	(15,956)	$	(16,393)
Animal Health		(6,249)		(6,494)		(24,207)		(21,889)
Consolidated Totals	$	(12,609)	$	(12,192)	$	(40,163)	$	(38,282)

The Company's reportable segments assets consisted of the following:

	September 30,		December 31,
(in thousands)	2022		2021
	(unaudited)
Segment assets
Human Health	$	39,916	$	42,250
Animal Health		128,693		115,580
Total	$	168,609	$	157,830

The reconciliation of segments assets to the consolidated assets is as follows:

	September 30,		December 31,
(in thousands)	2022		2021
	(unaudited)
Total assets for reportable segments	$	168,609	$	157,830
Less: Investment in subsidiary		(29,232)		(29,232)
Less: Intercompany loan		(88,090)		(75,333)
Consolidated Totals	$	51,287	$	53,265